Camrelizumab

卡瑞利珠单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameCamrelizumab
Drug Alias NameCarrizumab注射用卡瑞利珠单抗CarbarizumabCalizumabCarrilizumab +[17] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNasal Cavity CancerGastroesophageal Junction NeoplasmsSolid tumours +[50] 
Global Approved IndicationsNasopharyngeal CarcinomaHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2019/05/29
Country/TerritoryBelgiumUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPla General HospitalCrystalgenomics IncElevar Therapeutics Inc +[16] 
Inactive CompaniesHRYZ Biotech Co LtdGuangxi Medical UniversityPeking University +[5] 
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[29] 
Inactive IndicationsNasal Cavity CancerLung DiseasesRespiratory Tract Diseases +[21] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBank